

Greater Manchester Joint Formulary & RAG/DNP list change log

16 March 2023

The list below includes changes made in the last 12 months. For information on older updates, contact nuth.enquiries.gmmmg@nhs.net



Date	Chapter	Section	Change made	RAG/DNP list updated	Formulary updated	New chapter version no.
16/03/2023	1	1.5.3	Ozanimod for UC added as RED, in line with NICE TA828	Y	Y	7.7
16/03/2023	6	6.1.1.2	Insulin cost charts updated	n/a	Y	9.16
16/03/2023	6	6.1.1.3	Insulin needle cost chart updated	n/a	Y	9.16
16/03/2023	6	6.4.2	MHRA DSU link added: Topical testosterone (Testogel): risk of harm to children following accidental exposure. Jan	Y	Y	9.16
16/03/2023	6	6.7.2	Reulgolix/estradiol/norethisterone for fibroids added as GREEN (specialist advice) in line with NICE TA832	Y	Y	9.16
16/03/2023	10	10.1.3	Upadacitinib for active AS added as RED, in line with NICE TA829	n/a	Y	7.11
16/03/2023	11	11.4.1	Links to TA349 (dexamethasone for DMO) removed and replaced with links to TA824	n/a	Y	5.5
16/03/2023	RAG		Avacopan added as RED, in line with NICE TA825	Y	n/a	n/a
21/02/2023	9	9.1.4	Fostamatinib removed from DNP list and added to formulary as a RED drug, in line with NICE TA835	Y	Y	6.5
21/02/2023	10	10.1.1	Links to CG177 removed and replaced with links to updated guidance NG226.	n/a	Y	7.10
21/02/2023	10	10.1.5	Links to CG177 removed and replaced with links to updated guidance NG226. Advice on glucosamine and chondroitin replaced with updated advice on glucosamine and opioids.	n/a	Y	7.10
21/02/2023	RAG		MHRA DSU link added: Xaqua (metolazone) 5mg tablets: exercise caution when switching patients between metolazone preparations	Y	n/a	n/a
25/01/2023	RAG		Pentosan RAG status updated to RED, in line with FMESG decision from Jan 2020 and formulary position.	Y	n/a	n/a
23/01/2023	6	6.4	Minor corrections to links and formatting, in line with new HRT pathway	n/a	Y	9.15
17/01/2023	1	1.2	Medicines added to formulary to reflect newly approved hypersalivation guidance: hyoscine tablets and patches, atropine eye drops, glycopyrronium oral solution.	Y	Y	7.6
17/01/2023	6	6.1.1.1	Insuman Comb 50 removed from formulary - product discontinued	n/a	Y	9.14
17/01/2023	6	6.4.1	Section updated to reflect HRT guidance: addition of Bijuve, Elleste Duet Conti, tibolone, Estradot, Oestrogel, Sandrena,	n/a	Y	9.14
17/01/2023	6	6.4.2	Section updated to reflect HRT guidance: testosterone for low sexual desire in post-menopausal women updated to GREEN (specialist advice), and remains GREY	Y	Y	9.14
17/01/2023	7	7.2.1	Section updated to reflect HRT guidance: Gynest, Ortho-Gynest & Vagifem removed; Ovestin, Imvaggis, Vagirux, Estring added.	n/a	Y	7.2
17/01/2023	10	10.1.3	Links to NICE TA711 (guselkumab for psoriatic arthritis) removed and replaced with links to updated NICE TA815	Y	Y	7.9
17/01/2023	11	11.8.2.3	NICE TA820, brolucizumab for diabetic macular oedema, added	Y	Y	5.4
17/01/2023	13	13.5.3	Abrocitinib, tralokinumab & upadacitinib added as RED drugs, in line with NICE TA814	Y	Y	6.4
19/12/2022	1	1.3.1	Famotidine 20mg & 40 mg tablets added to formulary as GREEN as first choice H2 receptor antagonist replacing ranitidine.	Y	Y	7.5

Date	Chapter	Section	Change made	RAG/DNP list updated	Formulary updated	New chapter version no.
19/12/2022	2	2.12	the risk of cardiovascular events in people with raised triglycerides https://www.nice.org.uk/guidance/ta805 , ?note that pathway is pending	Y	Y	7.12
19/12/2022	2	2.12	Black triangle added against inclisiran	n/a	Y	7.12
19/12/2022	4	4.4	Modafinil RAG status updated to GREEN (following specialist initiation) following publication of information for primary care prescribers.	Y	Y	9.13
19/12/2022	4	4.2.1	RAG status for lurasidone updated to AMBER following publication of updated shared care protocol for atypical antipsychotics	Y	Y	9.14
19/12/2022	4	4.2.1	Paliperidone MR tablets added to formulary with AMBER status, in line with updated SCP	Y	Y	9.14
19/12/2022	4	4.8.1	Fenfluramine added as a RED drug as per NICE TA808: Fenfluramine for treating seizures associated with Dravet syndrome	Y	Y	9.14
19/12/2022	8	8.2	Imlifidase added as a RED drug as per NICE TA809: Imlifidase for desensitisation treatment before kidney transplant in people with chronic kidney disease	Y	Y	12.5
19/12/2022	9	9.1.3	Roxadustat added as RED as per NICE TA807: Roxadustat for treating symptomatic anaemia in chronic kidney disease	Y	Y	6.4
19/12/2022	9	9.2.1.1	Sodium zirconium cyclosilicate and patiomer sodium for hyperkalemia both updated to AMBER following publication	Y	Y	6.4
19/12/2022	10	10.1.3	Risankizumab added as RED per NICE TA803: Risankizumab for treating active psoriatic arthritis after inadequate	n/a	Y	7.8
19/12/2022	RAG	RAG	Metolazone - removed reference to unlicensed product, and added recommendation for brand name prescribing.	Y	n/a	n/a
19/12/2022	RAG	RAG	Add setmelanotide as RED as per NICE HST21: Setmelanotide for treating obesity caused by LEPR or POMC deficiency	Y	n/a	n/a
16/12/2022	1	1.5.2	Budesonide MR - amended to remove advice on specialist initiation, and add MGSG decision "counselling on the safe use of steroids should be provided by the specialist"	Y	Y	7.4
16/12/2022	3	3.4.2	MHRA DSU link added: Dupilumab Dupilumab (Dupixent ▼): risk of ocular adverse reactions and need for prompt management	n/a	Y	8.6
16/12/2022	6	6.1.2.3	Tirzepatide - statement added to clarify that tirzepatide has not considered by GMMMG pending NICE and shouldn't	Y	Y	9.13
16/12/2022	13	13.5.3	MHRA DSU link added: Dupilumab Dupilumab (Dupixent ▼): risk of ocular adverse reactions and need for prompt	n/a	Y	6.3
24/11/2022	1	1.5	Filgotinib added as RED for moderately to severely active ulcerative colitis, in line with NICE TA792	Y	Y	7.3
24/11/2022	1	1.5	Black triangle against Amgevita (adalimumab) removed; no longer applies to this product.	n/a	Y	7.3
24/11/2022	1	1.4.2	Teduglutide added as a RED drug, in line with NICE TA804	Y	Y	7.3
24/11/2022	2	2.3.2	Mexiletine for life-threatening ventricular arrhythmias added as RED	Y	Y	7.11
24/11/2022	4	4.3	Links to superseded NICE guideline CG90 removed and replaced with link so NG222: Depression in adults.	n/a	Y	9.12
24/11/2022	4	4.4	MHRA DSU link added: Methylphenidate long-acting (modified-release) preparations: caution if switching between	n/a	Y	9.12
24/11/2022	4	4.1.1	Adaflex added to formulary as first choice melatonin product.	Y	Y	9.12
24/11/2022	8	8.2.4	Black triangle for canakinumab removed; no longer applies to this product	n/a	Y	12.4
24/11/2022	8	8.2.4	Diroximel fumarate added as RED, in line with NICE TA794: diroximel fumarate for treating relapsing–remitting	Y	Y	12.4
24/11/2022	8	8.2.4	Link to NHSE commissioning policy multiple sclerosis updated	n/a	Y	12.4
24/11/2022	8	8.2.4	Link added to NICE NG220: Multiple sclerosis in adults: management	n/a	Y	12.4
24/11/2022	10	10.1.4	Link to superseded NICE TA164 (febuxostat for gout) removed and replaced with links to NICE NG219: Gout diagnosis and management.	n/a	Y	7.7
24/11/2022	11	11.8.2.2	Ranibizimab biosimilar added to formulary as first choice VEGF-A for NICE-approved indications	n/a	Y	5.3
24/11/2022	11	11.8.2.2	Faricimab added as RED in line with NICE TA799 & TA800	Y	Y	5.3

Date	Chapter	Section	Change made	RAG/DNP list updated	Formulary updated	New chapter version no.
07/11/2022	2	2.5.5.1	Dapagliflozin for CKD added as Green, in line with NICE TA775	Y	Y	7.10
07/11/2022	2	2.8.2	Edoxaban made first choice DOAC for atrial fibrillation only; formulary positions of the DOACs unchanged in other indications. Link added to GMMMG DOAC statement.	n/a	Y	7.10
07/11/2022	6	6.1.2.3	Sitagliptin moved to first choice DPP4 inhibitor; alogliptin moved to "alternative"	n/a	Y	9.12
07/11/2022	6	6.6.2	Romosozumab for severe osteoporosis added as RED, as per NICE TA791	Y	Y	9.12
07/11/2022	11	11.8.1	Simple eye ointment added to DNP list, criterion 3	Y	Y	5.2
07/11/2022	RAG		Entry for levetiracetam amended to clarify the RAG status applies to oral formulations, as per formulary	Y	n/a	n/a
14/10/2022	6	6.4.1.2	Micronised progesterone vaginal capsules (utrogestan) amended to GREEN (following specialist initiation), in line with CRG decision	Y	Y	9.11
26/09/2022	2	2.5.5.1	Empagliflozin for heart failure added as Green (specialist advice), in line with NICE TA773	Y	Y	7.9
26/09/2022	3	3.1.1	MHRA DSU link added: Nebulised asthma rescue therapy in children: home use of nebulisers in paediatric asthma should be initiated and managed only by specialists	n/a	Y	8.5
26/09/2022	4	4.3	Link to NICE NG215: Medicines associated with dependence or withdrawal symptoms: safe prescribing and withdrawal management for adults added to antidepressant section	n/a	Y	9.11
26/09/2022	4	4.4	Pitolisant for obstructive sleep apnoea added to DNP list (criterion 1)	Y	Y	9.11
26/09/2022	4	4.4	Solriamfetol for obstructive sleep apnoea added to DNP list (criterion 1)	Y	Y	9.11
26/09/2022	4	4.1.1	Link to NICE NG215: Medicines associated with dependence or withdrawal symptoms: safe prescribing and withdrawal management for adults added to z-drug section	n/a	Y	9.11
26/09/2022	4	4.1.2	Link to NICE NG215: Medicines associated with dependence or withdrawal symptoms: safe prescribing and withdrawal management for adults added to benzodiazepine section	n/a	Y	9.11
26/09/2022	4	4.7.2	Link to NICE NG215: Medicines associated with dependence or withdrawal symptoms: safe prescribing and withdrawal management for adults added to neuropathic pain section	n/a	Y	9.11
26/09/2022	4	4.7.3	Link to NICE NG215: Medicines associated with dependence or withdrawal symptoms: safe prescribing and withdrawal management for adults added to neuropathic pain section	n/a	Y	9.11
26/09/2022	4	4.7.4.2	MHRA DSU link added: Topiramate (Topamax): start of safety review triggered by a study reporting an increased risk of	n/a	Y	9.11
26/09/2022	4	4.8.1	Link to superseded NICE guidance CG137 removed and replaced with link to NG217 Epilepsies in children, young people and adults	n/a	Y	9.11
26/09/2022	4	4.8.1	MHRA DSU link added: Topiramate (Topamax): start of safety review triggered by a study reporting an increased risk of neurodevelopmental disabilities in children with prenatal exposure	n/a	Y	9.11
26/09/2022	5	5.3	Nirmatrelvir / ritonavir (Paxlovid) added to formulary as RED	Y	Y	7.4
26/09/2022	6	6.1.2.3	Lixisenatide removed from formulary following discontinuation of 10mcg and initiation packs. Note added that	Y	Y	9.9
26/09/2022	6	6.4.1.2	Micronised progesterone vaginal capsules added to formulary as GREEN for management of miscarriage, in line with	Y	Y	9.9
26/09/2022	6	6.6.2	Romosozumab for severe osteoporosis added as RED, as per NICE TA791	Y	Y	9.9
26/09/2022	8	8.3.4.2	Goserelin & leuprorelin added as AMBER for male breast cancer, with link to updated shared care protocol	n/a	Y	12.3
26/09/2022	10		Link to NG191 (COVID-19) added against baricitinib.	n/a	Y	7.6
26/09/2022	13	13.2	Emollients updated to align with primary care dermatology emollient ladder. First choice and alternatives changed in	n/a	Y	6.2
26/09/2022	13	13.9	Minoxidil foam added to DNP list and note added to clarify that minoxidil cream, lotion, ointment & solution are	Y	Y	6.2
26/09/2022	13		Link to NG191 (COVID-19) added against baricitinib.	n/a	Y	6.2

Date	Chapter	Section	Change made	RAG/DNP list updated	Formulary updated	New chapter version no.
26/09/2022	DNP		Anti-reflux milks added to DNP list, with link to CMPA policy	Y	n/a	n/a
26/09/2022	RAG		Elosulfase alfa RAG entry updated to replace link to superseded NICE HST2 with NICE HST19	Y	n/a	n/a
26/09/2022	RAG		Pegcetacoplan added as RED for treatment of PNH, in line with NICE TA778	Y	n/a	n/a
26/09/2022	RAG		Atidarsagene autotemcel added as RED, in line with NICE HST18	Y	n/a	n/a
26/09/2022	RAG		Selumetinib added as RED, in line with NICE HST20	Y	n/a	n/a
26/09/2022	RAG		Phenazone + lidocaine ear drops added to paediatric RAG list as GREEN, in line with NICE NG91	Y	n/a	n/a
05/08/2022	6	6.4.1	Note added: "Section under review; GMMMG HRT guidance is in development"	n/a	Y	9.9
05/08/2022	7	7.2.1	Note added: "Section under review; GMMMG HRT guidance is in development"	n/a	Y	7.1
27/07/2022	2	2.12	Wording updated to indicate that "An NHSE/NHS Digital tool to aid identification of eligible patients is available for	Y	Y	7.8
27/07/2022	2	2.9	Links to NICE guidance and MHRA Drug Safety Updates re-formatted for clarity. Broken links to MHRA DSUs for	n/a	Y	7.8
25/07/2022	2	2.12	Following wording now outdated, and has been removed: "The pricing structure agreed by NHSE/I means the NICE approved cost can only be accessed in primary care."	Y	Y	7.7
25/07/2022	4	4.6	Sativex added as RED, in line with NICE NG144: Cannabis-based medicinal products	Y	Y	9.10
22/07/2022	4	4.10.1	Chlordiazepoxide updated to GREEN	Y	Y	9.9
22/07/2022	4	4.7.4.2	Links to NICE TA631 (fremanezumab for preventing migraine) removed and replaced to updated NICE TA764.	Y	Y	9.9
22/07/2022	6	6.1.2.2	MHRA DSU link added: Metformin and reduced vitamin B12 levels: new advice for monitoring patients at risk	n/a	Y	9.8
22/07/2022	6	6.4.1.1	Added links to information on managing disruptions to HRT supplies.	n/a	Y	9.8
22/07/2022	RAG	10	Tofacitinib for JIA added to paediatric RAG list as RED	Y	n/a	n/a
22/07/2022	RAG	13	Secukinumab for psoriasis added to paediatric RAG list as RED	Y	n/a	n/a
22/06/2022	4	4.7.4	Updated to correct typos and add section on tension headache. Simple analgesics (paracetamol, aspirin, NSAIDs) added as per 4.7.4.1. Amitriptyline added for prophylaxis.	n/a	Y	9.8
17/06/2022	1	1.6.4	Restriction to macrogol 3350 removed, and statement added directing prescribers to choose the most cost-effective macrogol	n/a	Y	7.2
17/06/2022	2	2.5.2	Moxonidine entry updated to GREEN specialist initiation, to clarify position and align with with standard wording. Previously listed as: "Moxonidine (specialist initiation only)"	Y	Y	7.6
17/06/2022	3	3.4.2	Palforzia added to formulary as RED and GREY, only Only for use in people aged 18 and over if treatment started	Y	Y	8.4
17/06/2022	4	4.7	Whole section updated to align with updated GMMMG headache pathway	Y	Y	9.7
17/06/2022	4	4.7, 4.8	MHRA DSU link added: Pregabalin (Lyrica): findings of safety study on risks during pregnancy	n/a	Y	9.7
17/06/2022	4	4.7.4.1	Simple analgesics: ibuprofen (OTC), naproxen (unlicensed) and diclofenac (unlicensed) added	Y	Y	9.7
17/06/2022	4	4.7.4.1	Anti-emetics: prochlorperazine added (5mg tabs unlicensed, 3mg buccal tabs OTC)	Y	Y	9.7
17/06/2022	4	4.7.4.1	Combined preparations: aspirin with metoclopramide added. Paracetamol with isometheptene and paracetamol with	Y	Y	9.7

Date	Chapter	Section	Change made	RAG/DNP list updated	Formulary updated	New chapter version no.
17/06/2022	4	4.7.4.1	Triptans: zolmitriptan, frovatriptan, and rizatriptan tablets added as alternative choices. Zolmitriptan nasal spray added	Y	Y	9.7
17/06/2022	4	4.7.4.2	specialist advice), zonisamide (green, specialist advice), amitriptyline, nortriptyline (green, if intolerant to amitriptyline), candesartan (green), flunarazine (red),	Y	Y	9.7
17/06/2022	4	4.7.4.3	Acute treatment: zolmitriptan nasal spray and oxygen added	Y	Y	9.7
17/06/2022	4	4.7.4.3	Prophylaxis: verapamil added (green, specialist advice)	Y	Y	9.7
17/06/2022	6	6.6.2	MHRA DSU link added: Denosumab 60mg (Prolia): should not be used in patients under 18 years due to the risk of	n/a	Y	9.7
17/06/2022	8	8.2.4	Ponesimod for multiple sclerosis added as RED, in line with NICE TA767	Y	Y	12.2
17/06/2022	9	9.1.4	Link added to information on risk of thrombosis on discontinuation of anagrelide	n/a	Y	6.3
17/06/2022	10	10.1.3	Link to NICE TA768 added against upadacitinib	n/a	Y	7.4
17/06/2022	13	13.11.6	Link to NPSA alert on Inadvertent oral administration of potassium permanganate added	n/a	Y	6.1
17/06/2022	13	13.5.2	Brand name and formulation for Calcipotriol 50 micrograms/g, betamethasone dipropionate 0.05% removed from formulary, and replaced with: "Choose the most cost-effective option"	n/a	Y	6.1
17/06/2022	13	13.6.1	Strength of Epiduo gel removed, to align with primary care acne pathway	n/a	Y	6.1
17/06/2022	RAG		Odevixibat added to RAG list as RED, in line with NICE HST17	Y	n/a	n/a
20/05/2022	2	2.12	Bempedoic acid updated to green (specialist advice) from green (specialist initiation)	Y	Y	7.5
20/05/2022	3	3.4.2	Added dupilumab for severe asthma with type 2 inflammation as RED, as per NICE TA751.	Y	Y	8.3
20/05/2022	4	4.4	Solriamfetol for narcolepsy added as a RED drug, as per NICE TA758	Y	Y	9.5
20/05/2022	4	4.4	Modafinil updated to RED pending approval of information for primary care prescribers. Was previously RED pending	Y	Y	9.5
20/05/2022	4	4.7.3	Section updated to reflect updated GMMMG neuropathic pathway. Added nortriptyline (first line alternative) &	n/a	Y	9.5
20/05/2022	4	4.8.1	Cenobamate for focal onset seizures in epilepsy added as Green (following specialist initiation by a tertiary epilepsy	Y	Y	9.5
20/05/2022	5	5.3	Sotrovimab added as a RED drug as per NICE NG191	Y	Y	7.3
20/05/2022	6	6.1.2.3	Added link to NG203 (chronic kidney disease) to notes on SGLT2 inhibitors.	n/a	Y	9.6
20/05/2022	9	9.1.4	Added fostamatinib for refractory chronic immune thrombocytopenia to DNP list, as per NICE TA759	Y	Y	6.2
20/05/2022	10	10.2	Risdiplam added as a RED drug as per NICE TA755	Y	Y	7.3
20/05/2022	10	10.1.3	Updated belimumab entry to link to updated NICE guidance, NICE TA752	n/a	Y	7.3
20/05/2022	RAG		Liraglutide for obesity in people aged 12-17 added to DNP list.	Y	n/a	n/a
26/04/2022	3	3.2	Corrected typo on Ateectura Breezhaler	n/a	Y	8.1
26/04/2022	3	3.2	Corrected typo on Trixeo Aerosphere	n/a	Y	8.2
21/04/2022	2	2.3.2	MHRA DSU link added: Amiodarone (Cordarone X): reminder of risks of treatment and need for patient monitoring and	Y	Y	7.4
21/04/2022	2	2.4 & 2.9	Added link to NICE NG208: heart valve disease presenting in adults	n/a	Y	7.4
21/04/2022	3	3.1 & 3.2	Updated to reflect the GMMMG asthma and COPD management plans	n/a	Y	8.0
21/04/2022	4	4.10.2	Replaced superseded links to NICE NG92 with links to NG209: Tobacco: preventing uptake, promoting quitting and	n/a	Y	9.4
21/04/2022	4	4.10.2	Added link to GM tobacco dependency treatment guidelines	n/a	Y	9.4
21/04/2022	6	6.1.2.2	MHRA DSU link added: Metformin in pregnancy: study shows no safety concerns	n/a	Y	9.5
21/04/2022	6	6.1.2.3	Added link to NICE NG28	n/a	Y	9.5
21/04/2022	8	8.2.4	MHRA DSU link added: Cladribine (Mavenclad): new advice to minimise risk of serious liver injury	Y	Y	12.1
21/04/2022	9	9.1	Added crizlizumab as a RED drug, as per NICE TA743	Y	Y	6.1

Date	Chapter	Section	Change made	RAG/DNP list updated	Formulary updated	New chapter version no.
21/04/2022	9	9.1.1.2	Updated generic name of Monofer to ferric derisomaltose	Y	Y	6.1
21/04/2022	10	10.1.3	Added link to NICE TA744: Upadacitinib for treating moderate rheumatoid arthritis	Y	Y	7.2
21/04/2022	10	10.1.5	Updated link to GM EUR policy, Hyaluronic Acid injections for Osteoarthritis, to latest version	Y	Y	7.2
21/04/2022	RAG		Added givosiran to RAG list as a RED drug, as per NICE HST16	Y	n/a	n/a
06/04/2022	6	6.1.2.3	Type 1 diabetes indication for dapagliflozin removed, in line with change to licensed indications and MHRA DSU advice.		Y	9.4